Clovis Oncology Analyst Ratings
Clovis Oncology Analyst Ratings
While ratings are subjective and will change, the latest Clovis Oncology (CLVS) rating was a downgraded with a price target of $0.00 to $0.00. The current price Clovis Oncology (CLVS) is trading at is $0.28, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/10/2022 | — | JP Morgan | Downgrades | Neutral → Underweight | |
| 05/06/2022 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 05/05/2022 | 1338.33% | HC Wainwright & Co. | $5 → $4 | Maintains | Buy |
| 09/21/2021 | 3136.25% | HC Wainwright & Co. | $10 → $9 | Maintains | Buy |
| 08/05/2021 | 3495.83% | HC Wainwright & Co. | $12 → $10 | Maintains | Buy |
| 05/05/2021 | 4214.99% | HC Wainwright & Co. | $13 → $12 | Maintains | Buy |
| 11/06/2020 | 978.75% | SVB Leerink | $4 → $3 | Maintains | Underperform |
| 11/06/2020 | 5293.74% | HC Wainwright & Co. | $23 → $15 | Maintains | Buy |
| 05/22/2020 | 10327.9% | HC Wainwright & Co. | $33 → $29 | Reiterates | → Buy |
| 05/20/2020 | 1338.33% | SVB Leerink | $5 → $4 | Maintains | Underperform |
| 05/18/2020 | 11766.24% | HC Wainwright & Co. | $29 → $33 | Maintains | Buy |
| 05/06/2020 | 10327.9% | HC Wainwright & Co. | $27 → $29 | Reiterates | → Buy |
| 04/27/2020 | 1697.91% | SVB Leerink | → $5 | Downgrades | Market Perform → Underperform |
| 04/09/2020 | 2057.5% | B of A Securities | → $6 | Downgrades | Neutral → Underperform |
| 01/23/2020 | 3495.83% | B of A Securities | $7 → $10 | Maintains | Neutral |
| 11/19/2019 | 2776.66% | Evercore ISI Group | → $8 | Downgrades | Outperform → In-Line |
| 10/08/2019 | 978.75% | Goldman Sachs | $13 → $3 | Maintains | Sell |
| 09/24/2019 | — | SVB Leerink | Downgrades | Outperform → Market Perform | |
| 08/13/2019 | 2417.08% | B of A Securities | $13 → $7 | Downgrades | Buy → Neutral |
| 08/02/2019 | — | Guggenheim | Downgrades | Buy → Neutral | |
| 05/29/2019 | 5293.74% | Goldman Sachs | $17 → $15 | Downgrades | Neutral → Sell |
| 02/13/2019 | 14283.32% | HC Wainwright & Co. | → $40 | Initiates Coverage On | → Buy |
| 10/31/2018 | 14283.32% | Barclays | $58 → $40 | Maintains | Overweight |
| 10/31/2018 | 5653.33% | JP Morgan | $71 → $16 | Downgrades | Overweight → Neutral |
| 09/25/2018 | 10687.49% | Leerink Swann | → $30 | Initiates Coverage On | → Market Perform |
| 02/27/2018 | 30464.55% | Barclays | $105 → $85 | Maintains | Overweight |
| 02/27/2018 | 39454.12% | Stifel | $125 → $110 | Maintains | Buy |
| 02/22/2018 | — | Evercore ISI Group | Upgrades | In-Line → Outperform | |
| 02/22/2018 | — | RBC Capital | Upgrades | Sector Perform → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 2022 年 10 月 11 日 | — | 摩根大通 | 降級 | 中性 → 體重不足 | |
| 2022 年 6 月 5 日 | — | HC Wainwright & Co. | 降級 | 買入 → 中性 | |
| 05/05/2022 | 1338.33% | HC Wainwright & Co. | 5 美元 → 4 美元 | 維護 | 買 |
| 09/21/2021 | 3136.25% | HC Wainwright & Co. | 10 美元 → 9 美元 | 維護 | 買 |
| 08/05/2021 | 3495.83% | HC Wainwright & Co. | 12 美元 → 10 美元 | 維護 | 買 |
| 2021 年 5 月 5 日 | 4214.99% | HC Wainwright & Co. | 13 美元 → 12 美元 | 維護 | 買 |
| 11/06/2020 | 978.75% | SVB Leerink | 4 美元 → 3 美元 | 維護 | 表現不佳 |
| 11/06/2020 | 5293.74% | HC Wainwright & Co. | 23 美元 → 15 美元 | 維護 | 買 |
| 05/22/2020 | 10327.9% | HC Wainwright & Co. | 33 美元 → 29 美元 | 重申 | → 購買 |
| 05/20/2020 | 1338.33% | SVB Leerink | 5 美元 → 4 美元 | 維護 | 表現不佳 |
| 2020 年 5 月 18 日 | 11766.24% | HC Wainwright & Co. | 29 美元 → 33 美元 | 維護 | 買 |
| 2020 年 6 月 5 日 | 10327.9% | HC Wainwright & Co. | 27 美元 → 29 美元 | 重申 | → 購買 |
| 2020 年 4 月 27 日 | 1697.91% | SVB Leerink | → 5 美元 | 降級 | 市場表現 → 表現不佳 |
| 04/09/2020 | 2057.5% | B of A 類證券 | → 6 美元 | 降級 | 中性 → 跑贏大盤 |
| 01/23/2020 | 3495.83% | B of A 類證券 | 7 美元 → 10 美元 | 維護 | 中立 |
| 11/19/2019 | 2776.66% | Evercore ISI 集團 | → 8 美元 | 降級 | 跑贏大盤 → 在線 |
| 2019 年 8 月 10 日 | 978.75% | 高盛 | 13 美元 → 3 美元 | 維護 | 賣出 |
| 2019 年 9 月 24 日 | — | SVB Leerink | 降級 | 跑贏大盤 → 市場表現 | |
| 08/13/2019 | 2417.08% | B of A 類證券 | 13 美元 → 7 美元 | 降級 | 買入 → 中性 |
| 2019 年 2 月 8 日 | — | 古根海姆 | 降級 | 買入 → 中性 | |
| 05/29/2019 | 5293.74% | 高盛 | 17 美元 → 15 美元 | 降級 | 中性 → 賣出 |
| 02/13/2019 | 14283.32% | HC Wainwright & Co. | → 40 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 10/31/2018 | 14283.32% | 巴克萊 | 58 美元 → 40 美元 | 維護 | 超重 |
| 10/31/2018 | 5653.33% | 摩根大通 | 71 美元 → 16 美元 | 降級 | 超重 → 中性 |
| 2018 年 9 月 25 日 | 10687.49% | Leerink Swann | → 30 美元 | 啓動覆蓋範圍開啓 | → 市場表現 |
| 02/27/2018 | 30464.55% | 巴克萊 | 105 美元 → 85 美元 | 維護 | 超重 |
| 02/27/2018 | 39454.12% | Stifel | 125 美元 → 110 美元 | 維護 | 買 |
| 02/22/2018 | — | Evercore ISI 集團 | 升級 | 盤中 → 跑贏大盤 | |
| 02/22/2018 | — | 加拿大皇家銀行資本 | 升級 | 行業表現 → 跑贏大盤 |
What is the target price for Clovis Oncology (CLVS)?
克洛維斯腫瘤學（CLVS）的目標價格是多少？
The latest price target for Clovis Oncology (NASDAQ: CLVS) was reported by JP Morgan on November 10, 2022. The analyst firm set a price target for $0.00 expecting CLVS to fall to within 12 months (a possible -100.00% downside). 3 analyst firms have reported ratings in the last year.
摩根大通於2022年11月10日公佈了克洛維斯腫瘤學（納斯達克股票代碼：CLVS）的最新目標股價。該分析公司將目標股價定爲0.00美元，預計CLVS將在12個月內降至12個月內（可能下跌-100.00％）。去年有3家分析公司公佈了評級。
What is the most recent analyst rating for Clovis Oncology (CLVS)?
克洛維斯腫瘤學（CLVS）的最新分析師評級是多少？
The latest analyst rating for Clovis Oncology (NASDAQ: CLVS) was provided by JP Morgan, and Clovis Oncology downgraded their underweight rating.
摩根大通對克洛維斯腫瘤學（納斯達克股票代碼：CLVS）的最新分析師評級由摩根大通提供，克洛維斯腫瘤學下調了其減持評級。
When is the next analyst rating going to be posted or updated for Clovis Oncology (CLVS)?
克洛維斯腫瘤學（CLVS）的下一次分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Clovis Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Clovis Oncology was filed on November 10, 2022 so you should expect the next rating to be made available sometime around November 10, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Clovis Oncology的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。克洛維斯腫瘤學的最新評級是在2022年11月10日發佈的，因此您應該預計下一個評級將在2023年11月10日左右公佈。
Is the Analyst Rating Clovis Oncology (CLVS) correct?
分析師對克洛維斯腫瘤學（CLVS）的評級是否正確？
While ratings are subjective and will change, the latest Clovis Oncology (CLVS) rating was a downgraded with a price target of $0.00 to $0.00. The current price Clovis Oncology (CLVS) is trading at is $0.28, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的克洛維斯腫瘤學（CLVS）評級已下調，目標股價爲0.00美元至0.00美元。克洛維斯腫瘤學（CLVS）目前的交易價格爲0.28美元，超出了分析師的預期區間。
譯文內容由第三人軟體翻譯。
